Methylation analysis of MIR200 family in Mexican patients with colorectal cancer.
Carlos Rogelio Alvizo-RodriguezMaria de la Luz Ayala-MadrigalJesus Arturo Hernandez-SandovalHelen Haydee Fernanda Ramirez-PlascenciaChristian Octavio Gonzalez-VillaseñorNelly Margarita Macias-GomezJorge Peregrina-SandovalJose Miguel Moreno-OrtizJesus A Valenzuela-PerezJose Alfonso Cruz-RamosMelva Gutiérrez-AnguloPublished in: Journal of investigative medicine : the official publication of the American Federation for Clinical Research (2019)
The present study aimed to analyze the methylation pattern of the MIR200 family in the colorectal tissues and peripheral blood of colorectal cancer (CRC) patients. Previous informed consent, 102 samples of colorectal tissues (tumor and adjacent normal tissues) and 40 peripheral blood samples were collected from CRC patients. Additionally, we included a reference group of 40 blood samples. DNA extraction was done for colorectal tissues and peripheral blood. For methylation-specific PCR, we used bisulfite-treated DNA and controls for methylated and unmethylated DNA were included to each assay. PCR fragments were separated by 6% polyacrylamide gel electrophoresis. Methylation-positive and methylation-negative results were confirmed by bisulfite genomic sequencing technique. We analyzed 102 colorectal tissues and 40 blood samples from 51 CRC patients. MIR200B/MIR200A/MIR429 methylation analysis discloses no differences among tissues (p>0.05). However, MIR200C/MIR141 methylation showed differences between colorectal tissues and peripheral blood of CRC patients (p<0.0001) and mainly methylated alleles were observed in peripheral blood. These findings suggest a tissue-specific methylation pattern for the MIR200C/MIR141 promoter.
Keyphrases
- peripheral blood
- cell proliferation
- long non coding rna
- end stage renal disease
- gene expression
- dna methylation
- newly diagnosed
- chronic kidney disease
- ejection fraction
- long noncoding rna
- genome wide
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- high throughput
- single molecule
- single cell
- circulating tumor